Vasant Narasimhan, CEO of Novartis International since 2018, joins A16Z general partner Jorge Conde to discuss the transformation of the 250-year-old pharmaceutical giant. Narasimhan, a physician-scientist by training, previously worked on multi-drug resistant tuberculosis in Peru with luminaries like Jim Kim and Paul Farmer, experiences that continue to shape his focus on global health access today.

Under Narasimhan's leadership, Novartis executed one of the most dramatic corporate restructurings in pharmaceutical history, spinning off three public companies - consumer health (joint venture with GSK), Alcon (eye care devices), and Sandoz (generics) - while selling their Roche stake. This transformation from conglomerate to pure-play medicines company unlocked nearly $180 billion in value over six years.

Today's Novartis focuses on four therapeutic areas (oncology, immunology, neuroscience, and cardio-renal) and three platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. The company reaches 300 million patients globally with $55 billion in sales and approaches a $300 billion market cap, representing a fundamental shift toward specialized innovation rather than diversified healthcare.

The $180 Billion Transformation from Conglomerate to Pure Play

Novartis formed from the 1996 merger of Sandoz and Ciba-Geigy as a diversified healthcare conglomerate spanning consumer health, animal health, vaccines, Gerber baby food, and pharmaceuticals.

"We were misallocating capital. The return on capital varies tremendously between a consumer health business, a generics business, a device business, and a pharmaceuticals business" - Vasant, explaining the strategic rationale for focusing.

The six-year restructuring involved spinning off three public companies and selling the Roche stake, with Narasimhan noting "spinning off three public companies is a massive, massive undertaking."

"We unlocked almost $180 billion of value by doing that" through the transformation, demonstrating investor preference for focused rather than diversified pharmaceutical companies.

Cell Therapy Renaissance Through Immune System Reset

Cell therapies initially struggled with "complexity, cost of goods, profitability challenges" in cancer applications, leading to business model difficulties despite clinical success.

Georg Schett's work in Erlangen, Germany revealed cell therapies can "reset the immune system" for autoimmune diseases, creating unprecedented treatment opportunities.

"One of our Sentinel patients was an individual in bed. Six months later, no sign of disease. I mean, this is extraordinary" - Vasant describing the dramatic clinical results.

Manufacturing advances now enable "rapid platforms that take two days in the factory, eight days vein-to-vein time" compared to previous lengthy production cycles.

"Cell therapies and immunology, alongside immune reset, bispecific, trispecific. That is going to be a whole renaissance for cell therapy" with four pivotal trials and six early-stage programs underway.

Gene Therapy Success and Platform Challenges

Zolgensma treats spinal muscular atrophy, where "children would face certain death at two years of age" or live severely debilitated lives in wheelchairs.

The one-time gene therapy "costs over $2 million and it's reimbursed in 48 countries" due to extraordinary cost-effectiveness versus $10 million lifetime care costs.

"It's a success story, but it's an end-of-one story. This is not platformized yet" - Vasant acknowledging gene therapy remains challenging to scale across multiple diseases.

Key challenges include "trafficking these gene therapies to the right cell type, getting the expression as you hope, safety profile" proving more complex than anticipated.

siRNA as De-Risked Platform Technology

"siRNA is effectively a de-risk modality" representing decades of work from the early 1980s through breakthrough delivery solutions around 2015-2016.

PCSK9 siRNA for high cholesterol "works amazing" and enables once-yearly dosing, with particular success in China's market.

"Within the next five to seven years you could get a single injection that covers HMG-CoA reductase" and other cardiovascular targets, revolutionizing public health access.

Recent advances focus on trafficking siRNAs "into other parts of the body, into the muscle, into the brain, into the heart" beyond the original liver-directed applications.

Radioligand Therapy Supply Chain Mastery

Advanced Accelerator Applications, acquired in 2019, originated as "a spin-out from CERN, the particle accelerator outside of Geneva."

Two approved drugs generate significant revenue: prostate cancer therapy targeting PSMA "over $2 billion in sales" and neuroendocrine tumor treatment "approaching $1 billion in sales."

"After you activate the drug, you have between four and five days from the factory to the patient" requiring dedicated radioactive supply chains with precise timing.

"We have launched these products globally and are 99.9% on time on every dose" after seven years building the complex infrastructure at scale.

Within lutetium isotope platform, "we have eight or nine projects now in the clinic" though switching isotopes requires "radically different supply chain."

AI Reaches Pharmaceutical Tipping Point

"This year in 26 is finally when you started to see AI transact" with multiple large pharma-AI startup partnerships announced at JPMorgan Healthcare Conference.

Novartis deployed "3,000 scientists on the foundry platform" using Palantir's data lake, turning "data that used to take six months and now takes minutes."

"We have one of the highest numbers of AI licenses for Microsoft Copilot" as part of systematic scaling across the entire organization.

Personal AI applications include "agents that look at all of our historical decisions in R&D" to inform committee decisions and "create a podcast to listen to my integrated financial report."

Partnership with Isomorphic Labs focuses on "undruggable targets we've not been able to drug ourselves" using AlphaFold 3 technology for protein structure prediction.

China Competition Reshapes Global Biotech

"Last year, China had more licensing or exits than U.S. biotech or somewhere close to that" demonstrating the scale and speed of Chinese innovation.

"The NMPA simply moves incredibly fast for a first-in-human study. It's under a month now" compared to lengthy U.S. regulatory timelines.

Chinese biotechs leverage "very large integrated centers" to "generate that data extremely fast" in the critical de-risking phase one trials.

U.S. competitive response requires addressing "speed of trial bureaucracy" and ensuring "FDA is enabled to hire the scientists they need at scale."

Reimbursement Innovation for Breakthrough Therapies

"Over 90% of scripts in the U.S. are generic" with "generic drugs in the U.S. are the cheapest in the OECD," demonstrating the system rewards innovation then reduces prices.

Zolgensma's $2+ million price point achieves reimbursement because "the cost of caring for one of these patients is more like $10 million for their life."

"We were not successful in moving to those models where you kind of phase payment out because the systems just aren't ready for it" despite industry discussions about value-based medicine.

Preventative medicine faces multiple barriers: "the system is designed to care for the sick, not to prevent" and policies like IRA that "cap your patent life" before long trials complete.